MedTrace Logo

Low Remifentanil Target Controlled Infusions for Cardiac Surgery

NCT02033629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-07-18

No results posted yet for this study

Summary

The development of target effect-site controlled concentrations (TCI) of remifentanil have gained increasing acceptance during cardiac surgery as regarding the resulting of hemodynamic stability and early extubation. The use of low-dose opioid technique has been progressively used nowadays because of its ceiling effect to attenuate cardiovascular responses to noxious stimuli. We hypothesize that the use of low target remifentanil effect site concentrations may provide comparable shorter times to tracheal extubation and hemodynamic stability to the use of high remifentanil Ce during target-controlled propofol anesthesia for cardiac surgery.

Conditions

  • Cardiac Surgery

Interventions

DRUG

Ce 1 ng/ml

TCI Remifentanil Ce 1 ng/ml

DRUG

Ce 2 ng/ml

TCI Remifentanil Ce 2 ng/ml

DRUG

Ce 3 ng/ml

TCI Remifentanil Ce 3 ng/ml

Sponsors & Collaborators

  • Imam Abdulrahman Bin Faisal University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2019-05-01
Completion
2019-05-15

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033629 on ClinicalTrials.gov